342 results on '"Drummer, Heidi"'
Search Results
2. Antibody mechanisms of protection against malaria in RTS,S-vaccinated children: a post-hoc serological analysis of phase 2 trial
3. B-cell characteristics define HCV reinfection outcome
4. COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 Variants
5. Accuracy and precision of a point of care SARS-CoV-2 antigen rapid diagnostic test assessed in an Australian cohort
6. An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development
7. Infectious KoRV-related retroviruses circulating in Australian bats
8. Serological responses and clinical outcomes following a three‐dose primary COVID‐19 vaccine schedule in kidney transplant recipients and people on dialysis.
9. Frequent occurrence of low-level positive autoantibodies in chronic hepatitis C
10. Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine
11. Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapy
12. Dimeric immunoglobulin A as a novel diagnostic marker of measles infection
13. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments
14. Joint statement in support of hepatitis C human challenge studies
15. Third dose COVID-19 mRNA vaccine enhances IgG4 isotype switching and recognition of Omicron subvariants by memory B cells after with mRNA but not adenovirus priming
16. Serological assays to measure dimeric IgA antibodies in SARS‐CoV‐2 infections
17. Statement in Support of: “Virology under the Microscope—a Call for Rational Discourse”
18. Enhanced stability of the SARS CoV-2 spike glycoprotein following modification of an alanine cavity in the protein core
19. COVID-19 adenoviral vector vaccination elicits a robust memory B cell response with the capacity to recognize Omicron BA.2 and BA.5 variants
20. Joint statement in support of hepatitis C human challenge studies
21. The case for a universal hepatitis C vaccine to achieve hepatitis C elimination
22. Validation of a novel point‐of‐care test for alanine aminotransferase measurement: A pilot cohort study
23. B Cell Signatures and Antibody Imprinting Define HCV Reinfection Outcome
24. The second COVID‐19 mRNA vaccine dose enhances the capacity of Spike‐specific memory B cells to bind Omicron BA.2
25. Enhanced stability of the SARS CoV-2 spike glycoprotein trimer following modification of an alanine cavity in the protein core
26. Validation of novel point‐of‐care test for alanine aminotransferase measurement: A pilot cohort study
27. Double-dose mRNA vaccination to SARS-CoV-2 progressively increases recognition of variants-of-concern by Spike RBD-specific memory B cells
28. Point-of-Care Diagnostics for Diagnosis of Active Syphilis Infection: Needs, Challenges and the Way Forward
29. The second COVID‐19 mRNA vaccine dose enhances the capacity of Spike‐specific memory B cells to bind Omicron BA.2.
30. A pan‐genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice
31. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs
32. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2
33. An antigenically diverse, representative panel of envelope glycoproteins for HCV vaccine development
34. The Inaugural Australian Centre for Hepatitis Virology Public Panel Discussion on Viral Hepatitis Research—Lessons in Scientific Community Outreach
35. Delivery of a foreign epitope by sharing amino acid residues with the carrier matrix
36. Dimeric IgA is a specific biomarker of recent SARS-CoV-2 infection
37. Antibodies to the high-density lipoprotein receptor SR-B1 potently inhibit hepatitis C virus replication in vivo: New avenues for preventing reinfection of the liver following transplantation
38. To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity
39. Reanalysis of the Pfizer mRNA BNT162b2 SARS-CoV-2 vaccine data fails to find any increased efficacy following the boost: Implications for vaccination policy and our understanding of the mode of action
40. Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin
41. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence
42. Rapid and lasting generation of B-cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 disease and convalescence
43. 10th Lorne Infection and Immunity Conference 2020
44. Tenth Scientific Biennial Meeting of the Australasian Virology Society—AVS10 2019
45. Striving for Hepatitis C Elimination: The Role of a Vaccine
46. B cell immunodominance in primary hepatitis C virus infection
47. TCD8 response in diverse outcomes of recurrent exposure to hepatitis C virus
48. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users
49. A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus
50. Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T-helper epitopes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.